Founded in 2018, Verve Therapeutics Inc is a biotech company specialising in gene-editing techniques for the treatment of coronary arteries and cardiovascular diseases.
The first two VERV.O programs target PCSK9 and ANGPTL3, two genes that have been confirmed by human genetics and pharmacology as markers for lowering blood lipids. The company completed its initial public offering on the Nasdaq in June 2021, generating $266.7 million in gross revenue.
Verve Therapeutics Inc stock has had increased awareness and popularity among investors recently. FxPro clients can buy and also sell this asset as a CFD, speculating on the price changes.
On the page above, there is an online quote chart, as well as trading conditions applicable to this security.
For effective trading on the stock market, we recommend you check the stock prices regularly. Also, follow the corporate reports and news about the company's activities that are published on major analytical portals.
One of the most important things to pay attention to is upcoming earnings releases and dividend payment dates. You can check the monthly schedule on the Dividend & Earnings Calendar on the FxPro website. If you have a Buy position open on the ex-dividend date, your trading account will be credited with the dividend net of any withholding taxes. In the case of holding a Sell position, the whole dividend will be debited from your account. If you have questions about this, our customer support team are on hand to assist.
Start Trading VERV.O CFD Stocks with FxPro Today!
고객 계좌
FxPro는 1999년부터 클라이언트에게 온라인 거래 서비스를 제공해오고 있으며 현재 전 세계 173개국에서 서비스를 진행하고 있습니다.
수상
FxPro는 업계에서 꾸준히 인정을 받아왔으며, 양질의 서비스로 지금까지 127개의 국제상을 수상했습니다.
고객지원
저희의 다중 언어 지원 서비스 팀은 최고 수준의 지원을 제공하기 위해 24시간 일하고 있습니다.
산업 규정
FxPro는 전 세계적으로 가장 신뢰받는 금융 규제 기관 중 하나인 영국 FCA의 승인을 포함하여 여러 관활권의 엄격한 규제 감독을 받으며 운영되고 있습니다.
